Stock Events

Stock Events

Eiger BioPharmaceuticals 

€0.21
17
+€0+0% Friday 07:02

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

23AugExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
-7.5
-5.11
-2.71
-0.32
Expected EPS
-3.3
Actual EPS
N/A

Financials

-714.45%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
12.93MRevenue
-92.41MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 72C1.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences is a biopharmaceutical company that competes with Eiger in the development of treatments for viral diseases, including hepatitis delta virus (HDV).
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, competing with Eiger in areas such as infectious disease treatment.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie competes with Eiger in researching and developing treatments for various diseases, including viral infections, leveraging its biopharmaceutical capabilities.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals is involved in creating antiviral drugs among other treatments, presenting competition to Eiger in the infectious disease market.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline is a large pharmaceutical company that competes with Eiger in the development of vaccines and treatments for viral diseases.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol Myers Squibb is a global biopharmaceutical company that develops drugs for various diseases, including viral infections, competing with Eiger's focus areas.
Pfizer
PFE
Mkt Cap153.59B
Pfizer is a global pharmaceutical corporation that competes with Eiger in the development and commercialization of antiviral drugs.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Eiger in the research and development of treatments for infectious diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is known for its innovative treatments and competes with Eiger in the development of therapies for infectious diseases.
Novartis
NVS
Mkt Cap280.79B
Novartis is a global healthcare company that competes with Eiger in the development of new therapies for diseases, including viral infections.

About

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Show more...
CEO
Mr. David A. Cory M.B.A., MBA, R.Ph, R.Ph.
Employees
51
Country
United States
ISIN
US28249U1051
WKN
000A2AF9X

Listings

STU
DE
72C.STU

0 Comments

Share your thoughts

FAQ

What is Eiger BioPharmaceuticals stock price today?▼
The current price of 72C1.F is €0.21 EUR — it has increased by +0% in the past 24 hours. Watch Eiger BioPharmaceuticals stock price performance more closely on the chart.
What is Eiger BioPharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eiger BioPharmaceuticals stocks are traded under the ticker 72C1.F.
What is Eiger BioPharmaceuticals revenue for the last year?▼
Eiger BioPharmaceuticals revenue for the last year amounts to 12.93M EUR.
What is Eiger BioPharmaceuticals net income for the last year?▼
72C1.F net income for the last year is -92.41M EUR.
How many employees does Eiger BioPharmaceuticals have?▼
As of April 29, 2026, the company has 51 employees.
In which sector is Eiger BioPharmaceuticals located?▼
Eiger BioPharmaceuticals operates in the Health & Wellness sector.
When did Eiger BioPharmaceuticals complete a stock split?▼
Eiger BioPharmaceuticals has not had any recent stock splits.
Where is Eiger BioPharmaceuticals headquartered?▼
Eiger BioPharmaceuticals is headquartered in Palo Alto, United States.